NASDAQ:UNCY Unicycive Therapeutics Q2 2026 Earnings Report $4.55 -0.15 (-3.19%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$4.58 +0.03 (+0.64%) As of 10/1/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Unicycive Therapeutics EPS ResultsActual EPS-$0.06Consensus EPS -$0.47Beat/MissBeat by +$0.41One Year Ago EPSN/AUnicycive Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$22.22 millionBeat/MissN/AYoY Revenue GrowthN/AUnicycive Therapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time7:00AM ETUpcoming EarningsUnicycive Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Unicycive Therapeutics Earnings HeadlinesDEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsOctober 1 at 4:00 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmOctober 1 at 12:00 PM | globenewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallStOctober 1 at 10:11 AM | prnewswire.comUnicycive Therapeutics Appoints Meredith Manning to Board of DirectorsOctober 1 at 7:05 AM | globenewswire.comHC Wainwright Issues Optimistic Outlook for UNCY EarningsOctober 1 at 6:12 AM | americanbankingnews.comSee More Unicycive Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email. Email Address About Unicycive TherapeuticsUnicycive Therapeutics (NASDAQ:UNCY) is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company’s lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis. Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream. Unicycive is advancing the therapy through clinical development and has positioned it as a potential treatment option for patients who require long-term phosphate management. Unicycive Therapeutics is headquartered in the United States and serves the global kidney-care market through the development of its pharmaceutical programs. The company is led by Chief Executive Officer Shalabh Gupta, M.D., and its shares trade on the Nasdaq Capital Market under the symbol UNCY.View Unicycive Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
